Clinical Trials Browser

Triple Negative Breast Neoplasms × sacituzumab govitecan × 30 days × Clear all

NCT04468061 2026-02-27

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms